Released Nov 9, 2021, after the close
10-Q filed Nov 9, 2021, 40 days after period end · 0001636422-21-000077
Q3 2021 · 10-Q
Revenue$61.74M$61.74M +30.8% vs Q3 2020+3.5% vs Q2 2021
Net Income-$40.01M-$40.01M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.82-$0.82 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$42,249,000N/M
Operating Cash Flowderived-$5,360,000N/M
Free Cash Flowderived-$7,049,000N/M
Margins · derived
Operating margin-68.4%−18.7 pt vs Q3 2020
Net margin-64.8%−6.9 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $61.74M | $47.19M | $39.42M | $32.87M |
| Net Income | -$40.01M | -$27.33M | -$21.42M | -$16.88M |
| EPS Diluted | -$0.82 | -$0.68 | -$1.40 | -$3.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR